ARNEO trial

Prof. Joniau elaborates on his game changing lecture at EAU22 “Randomised phase II trial of neoadjuvant degarelix with or without apalutamide prior to radical prostatectomy for unfavorable intermediate- and high-risk prostate cancer”.